Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Relapsed/Refractory ALL
NCT03207542Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of daratumumab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Response Rate at 12 weeks and Adverse Events. Planned start Jul 2018; status: withdrawn.
02
Drugs
daratumumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03207542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207542.